California Resources Corporation·Energy
California Resources Corporation operates as an independent oil and natural gas company. The company explores for, produces, gathers, processes, and markets crude oil, natural gas, and natural gas liquids for marketers, California refineries, and other purchasers that have access to transportation and storage facilities. As of December 31, 2021, it had interests in approximately 1.9 million net mineral acres with proved reserves totaled an estimated 480 million barrels of oil equivalent. The company also engages in the generation and sale of electricity to the local utility and the grid. The company was incorporated in 2014 and is based in Santa Clarita, California.
Energy
Oil & Gas Exploration & Production
1,550
2020-10-28
1.03

While the two-week ceasefire came as a relief to many, especially after President Trump had ramped up the rhetoric, the reality is that while boats can move through the Strait of Hormuz, Bank of America reported that a stunning 11 million barrels per day of production remains shut in.

SG Americas Securities LLC boosted its stake in shares of California Resources Corporation (NYSE: CRC) by 107.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,300 shares of the oil and gas producer's stock after acquiring an additional 14,665 shares during

Flowserve, California Resources and Globus Medical stand out as sales-growth buys as oil spikes and Iran-Strait tensions shake markets.

LONG BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) plans to release its first quarter 2026 financial results on Tuesday, May 5th after market close.

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogs KAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX models Multiple combination opportunities with IDE574 and IDEAYA's proprietary pipeline Potential first-in-class and best-in-class preclinical profile will be presented at AACR 2026 SOUTH SAN FRANCISCO, Calif., April 6, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 dose escalation trial evaluating IDE574, a potential first-in-class oral small molecule equipotent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7 paralogs, both of which have been shown to support cancer cell survival.

Allspring Global Investments Holdings LLC boosted its position in California Resources Corporation (NYSE: CRC) by 2,349.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 234,797 shares of the oil and gas producer's stock after acquiring an additional 225,210 shares during the period. Allspring Global